Plasmodium vivax remains responsive to chloroquine with primaquine treatment regimen

A prospective cohort study from tertiary care teaching hospital in southern India

Kavitha Saravu, Vasudeva Acharya, Krishna Kumar, Rishikesh Kumar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We conducted this prospective study among 110 symptomatic Plasmodium vivax patients attending the Kasturba Hospital, Manipal, India, in order to evaluate their clinico-laboratory profile during July 2007–July 2009. Complications observed among patients were: anaemia (46.4%; 95% confidence interval [CI], 37.08–55.72%); thrombocytopenia (68.2%; 95% CI, 59.5–76.9%); leucopenia (29.1%; 95% CI, 20.61–37.59%); hyperbilirubinaemia (20%; 95% CI, 12.53–27.47%); non-oliguric renal failure (10.9%; 95% CI, 5.08–16.72%); elevated serum transaminases (33.6%; 95% CI, 24.77–42.43%); hypotension (8.2%; 95% CI, 3.07–13.33%); hepatomegaly (27.3%; 95% CI, 18.97–35.63%); and splenomegaly and jaundice in 12.7% (95% CI, 6.48–18.92%). The 99% chloroquine response and zero mortality observed in this study of vivax malaria are encouraging points for practicing physicians.

Original languageEnglish
Pages (from-to)163-164
Number of pages2
JournalTropical Doctor
Volume42
Issue number3
DOIs
Publication statusPublished - 01-01-2012

Fingerprint

Primaquine
Plasmodium vivax
Chloroquine
Tertiary Healthcare
Teaching Hospitals
India
Cohort Studies
Prospective Studies
Confidence Intervals
Therapeutics
Vivax Malaria
Hyperbilirubinemia
Hepatomegaly
Splenomegaly
Leukopenia
Transaminases
Jaundice
Thrombocytopenia
Hypotension
Renal Insufficiency

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

@article{8d61ea91174f45f5bfdc13ae458c6479,
title = "Plasmodium vivax remains responsive to chloroquine with primaquine treatment regimen: A prospective cohort study from tertiary care teaching hospital in southern India",
abstract = "We conducted this prospective study among 110 symptomatic Plasmodium vivax patients attending the Kasturba Hospital, Manipal, India, in order to evaluate their clinico-laboratory profile during July 2007–July 2009. Complications observed among patients were: anaemia (46.4{\%}; 95{\%} confidence interval [CI], 37.08–55.72{\%}); thrombocytopenia (68.2{\%}; 95{\%} CI, 59.5–76.9{\%}); leucopenia (29.1{\%}; 95{\%} CI, 20.61–37.59{\%}); hyperbilirubinaemia (20{\%}; 95{\%} CI, 12.53–27.47{\%}); non-oliguric renal failure (10.9{\%}; 95{\%} CI, 5.08–16.72{\%}); elevated serum transaminases (33.6{\%}; 95{\%} CI, 24.77–42.43{\%}); hypotension (8.2{\%}; 95{\%} CI, 3.07–13.33{\%}); hepatomegaly (27.3{\%}; 95{\%} CI, 18.97–35.63{\%}); and splenomegaly and jaundice in 12.7{\%} (95{\%} CI, 6.48–18.92{\%}). The 99{\%} chloroquine response and zero mortality observed in this study of vivax malaria are encouraging points for practicing physicians.",
author = "Kavitha Saravu and Vasudeva Acharya and Krishna Kumar and Rishikesh Kumar",
year = "2012",
month = "1",
day = "1",
doi = "10.1258/td.2012.120038",
language = "English",
volume = "42",
pages = "163--164",
journal = "Tropical Doctor",
issn = "0049-4755",
publisher = "SAGE Publications Ltd",
number = "3",

}

Plasmodium vivax remains responsive to chloroquine with primaquine treatment regimen : A prospective cohort study from tertiary care teaching hospital in southern India. / Saravu, Kavitha; Acharya, Vasudeva; Kumar, Krishna; Kumar, Rishikesh.

In: Tropical Doctor, Vol. 42, No. 3, 01.01.2012, p. 163-164.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Plasmodium vivax remains responsive to chloroquine with primaquine treatment regimen

T2 - A prospective cohort study from tertiary care teaching hospital in southern India

AU - Saravu, Kavitha

AU - Acharya, Vasudeva

AU - Kumar, Krishna

AU - Kumar, Rishikesh

PY - 2012/1/1

Y1 - 2012/1/1

N2 - We conducted this prospective study among 110 symptomatic Plasmodium vivax patients attending the Kasturba Hospital, Manipal, India, in order to evaluate their clinico-laboratory profile during July 2007–July 2009. Complications observed among patients were: anaemia (46.4%; 95% confidence interval [CI], 37.08–55.72%); thrombocytopenia (68.2%; 95% CI, 59.5–76.9%); leucopenia (29.1%; 95% CI, 20.61–37.59%); hyperbilirubinaemia (20%; 95% CI, 12.53–27.47%); non-oliguric renal failure (10.9%; 95% CI, 5.08–16.72%); elevated serum transaminases (33.6%; 95% CI, 24.77–42.43%); hypotension (8.2%; 95% CI, 3.07–13.33%); hepatomegaly (27.3%; 95% CI, 18.97–35.63%); and splenomegaly and jaundice in 12.7% (95% CI, 6.48–18.92%). The 99% chloroquine response and zero mortality observed in this study of vivax malaria are encouraging points for practicing physicians.

AB - We conducted this prospective study among 110 symptomatic Plasmodium vivax patients attending the Kasturba Hospital, Manipal, India, in order to evaluate their clinico-laboratory profile during July 2007–July 2009. Complications observed among patients were: anaemia (46.4%; 95% confidence interval [CI], 37.08–55.72%); thrombocytopenia (68.2%; 95% CI, 59.5–76.9%); leucopenia (29.1%; 95% CI, 20.61–37.59%); hyperbilirubinaemia (20%; 95% CI, 12.53–27.47%); non-oliguric renal failure (10.9%; 95% CI, 5.08–16.72%); elevated serum transaminases (33.6%; 95% CI, 24.77–42.43%); hypotension (8.2%; 95% CI, 3.07–13.33%); hepatomegaly (27.3%; 95% CI, 18.97–35.63%); and splenomegaly and jaundice in 12.7% (95% CI, 6.48–18.92%). The 99% chloroquine response and zero mortality observed in this study of vivax malaria are encouraging points for practicing physicians.

UR - http://www.scopus.com/inward/record.url?scp=84864056035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864056035&partnerID=8YFLogxK

U2 - 10.1258/td.2012.120038

DO - 10.1258/td.2012.120038

M3 - Article

VL - 42

SP - 163

EP - 164

JO - Tropical Doctor

JF - Tropical Doctor

SN - 0049-4755

IS - 3

ER -